The United States market has seen a flat performance over the last week but is up 19% over the past year, with earnings forecasted to grow by 17% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable conditions.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Fabrinet | 20.12% | 22.27% | ★★★★★★ |
| TG Therapeutics | 21.54% | 21.27% | ★★★★★★ |
| Lumentum Holdings | 43.99% | 56.54% | ★★★★★★ |
| AnaptysBio | 20.47% | 48.14% | ★★★★★★ |
| Praxis Precision Medicines | 64.64% | 71.33% | ★★★★★★ |
| Insmed | 32.10% | 66.44% | ★★★★★★ |
| Madrigal Pharmaceuticals | 27.97% | 63.67% | ★★★★★★ |
| Syndax Pharmaceuticals | 30.25% | 69.94% | ★★★★★★ |
| Travere Therapeutics | 24.05% | 52.97% | ★★★★★★ |
| Precigen | 34.82% | 55.42% | ★★★★★★ |
Click here to see the full list of 24 stocks from our US High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
TG Therapeutics (TGTX)
Simply Wall St Growth Rating: ★★★★★★
Overview: TG Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative treatments for B-cell mediated diseases globally, with a market cap of $6.97 billion.
Operations: TG Therapeutics focuses on developing and commercializing treatments for B-cell mediated diseases, generating revenue primarily from its biotechnology segment, which accounts for $799.54 million.
TG Therapeutics has demonstrated a remarkable earnings growth of 630.2% over the past year, significantly outpacing the biotech industry's average of 67.9%. This surge is supported by a robust R&D framework, with recent announcements highlighting advancements in multiple sclerosis (MS) and schizophrenia treatments. Notably, the company's revenue is projected to grow at an annual rate of 21.5%, surpassing the US market forecast of 12.9%. Moreover, TG Therapeutics raised its full-year revenue guidance to approximately $950 million, reflecting confidence in its ongoing and upcoming product pipelines which include novel therapies like BRIUMVI for MS and other autoimmune disorders. These strategic developments suggest a strong potential for sustained growth, driven by innovative treatments and an expanding market presence.
- Unlock comprehensive insights into our analysis of TG Therapeutics stock in this health report.
Explore historical data to track TG Therapeutics' performance over time in our Past section.
Precigen (PGEN)
Simply Wall St Growth Rating: ★★★★★★
Overview: Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company that focuses on developing gene and cell therapies for diseases in immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of approximately $2.51 billion.
Operations: Precigen focuses on developing gene and cell therapies using precision technology, primarily generating revenue from its biotechnology startups segment, which amounts to $85.72 million.
Precigen's recent financial turnaround is noteworthy, with a jump in Q2 revenue to $54.98 million from just $0.856 million the previous year and a shift to a net income of $20.07 million from a prior net loss of $26.64 million. This resurgence is underpinned by innovative therapies like PAPZIMEOS for recurrent respiratory papillomatosis, which not only received FDA approval but also exclusive market rights for seven years, enhancing its competitive edge in the biotech sector. Despite dropping from several Russell indexes, these developments suggest robust potential for growth fueled by strategic product approvals and market exclusivity.
- Get an in-depth perspective on Precigen's performance by reading our health report here.
Gain insights into Precigen's historical performance by reviewing our past performance report.
Zymeworks (ZYME)
Simply Wall St Growth Rating: ★★★★★★
Overview: Zymeworks Inc. is a biotechnology company focused on developing biotherapeutics for cancer, inflammation, and autoimmune diseases, with a market cap of $1.71 billion.
Operations: Zymeworks generates revenue primarily from the development of next-generation multifunctional biotherapeutics, amounting to $37.13 million. The company is engaged in creating innovative treatments targeting cancer, inflammation, and autoimmune diseases.
Zymeworks Inc. faces challenges with a recent net loss of $45.02 million in Q2 2026, contrasting sharply with a net income from the previous year. Despite this setback, the company's strategic moves including a notable share repurchase of 1,971,454 shares for $49.4 million and its acquisition plans with Theravance Biopharma signal robust efforts to bolster financial health and market position. Notably, Zymeworks is navigating through regulatory milestones that could potentially enhance its revenue streams significantly; it anticipates up to $440 million in combined approval and regulatory milestones globally which could pivot its current financial trajectory and reinforce its investment in R&D to drive long-term growth.
Where To Now?
- Gain an insight into the universe of 24 US High Growth Tech and AI Stocks by clicking here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com